Clinical trials: Stage IIIC Non-Small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
This study is to evaluate the tolerability and safety of ONO-7475 in combination with osimertinib in the first-line treatment of patients with EGFR-mutated, stage IIIB/IIIC/IV or recurrent non-small cell lung cancer (NSCLC)…
- Conditions
- Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer
- Trial name
- NCT06525246
- Testing
- ONO-7475, Osimertinib Mesylate
- Where
- 13 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.
This is an observational study, aiming to investigate whether the ctDNA dynamics analyzed by the K-TrackTM assay could predict early response to Tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung…
- Conditions
- Non Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT06167460
- Where
- Vietnam
- Volunteers
- 50 people
- Sponsor
- Gene Solutions
Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV
A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
This is a phase Ib/II , open-label, multicenter single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 combined with Carboplatin and Pemetrexed/ Paclitaxel as…
- Trial name
- NCT04647344
- Testing
- AK104 plus Carboplatin and Pemetrexed, AK104 plus Carboplatin and paclitaxel
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Akeso
NSCLC, Stage IV, NSCLC Stage IIIB
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
Open-label, Phase 2, single treatment arm, 3 cohorts
- Conditions
- NSCLC, Stage IV, NSCLC Stage IIIB, NSCLC, Stage IIIC, NSCLC, Recurrent
- Trial name
- RAIN (NCT03805841)
- Testing
- tarloxotinib bromide
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 41 people
- Sponsor
- Rain Oncology Inc